Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Competitors
The companies most similar to Kiniksa Pharmaceuticals are Neurocrine Biosciences (NBIX), Lantheus Holdings (LNTH) and Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX). Kiniksa Pharmaceuticals trades at 72.5x earnings, against a median of 19.9x for the 10 of these companies with a P/E. By market cap, Kiniksa Pharmaceuticals ranks 5th of the 13 companies on this page; United Therapeutics (UTHR) is the largest at $25.18B.
Peer Comparison
KNSA's revenue growth of 58.1% is above the peer median of 10.7%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals (KNSA) | $7.57B | 72.5x | 7.8x | 11.6% | N/A | 58.1% | 0.00% |
| Neurocrine Biosciences Inc (NBIX) | $16.94B | 18.4x | 4.5x | 19.0% | N/A | 41.2% | 0.00% |
| Lantheus Holdings Inc (LNTH) | $6.64B | 17.9x | 4.5x | 17.3% | 14.8% | 1.5% | 0.00% |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $7.45B | 21.4x | 2.2x | 4.2% | 11.6% | 10.0% | 0.00% |
| Xeris Pharmaceuticals Inc (XERS) | $3.04B | 139.2x | 8.2x | -1.8% | 15.5% | 44.2% | 0.00% |
| Elanco Animal Health (ELAN) | $13.39B | 23.2x | 2.6x | -2.9% | 1.6% | 11.3% | 0.00% |
| Dr. Reddy’s Laboratories Ltd ADR (RDY) | $12.29B | 39.6x | 3.5x | 8.5% | 5.7% | -1.5% | 0.44% |
| Indivior PLC Ordinary Shares (INDV) | $4.28B | 6.6x | 2.4x | 32.8% | 109.0% | 13.4% | 0.00% |
| Hims Hers Health Inc (HIMS) | $4.62B | N/A | 1.5x | -6.7% | -11.1% | 48.6% | 0.00% |
| HUTCHMED DRC (HCM) | $2.59B | N/A | 4.7x | 3.3% | -2.4% | 0.2% | 0.00% |
| BioCryst Pharmaceuticals Inc (BCRX) | $1.96B | 4.4x | 2.0x | -37.4% | 24937.1% | 13.1% | 0.00% |
| Bausch Health Companies Inc (BHC) | $3.13B | 1.7x | 0.3x | -7.6% | 6.3% | 9.7% | 0.00% |
| United Therapeutics Corporation (UTHR) | $25.18B | 22.2x | 7.9x | 38.6% | N/A | 4.1% | 0.00% |
| Peer median | $5.63B | 19.9x | 3.0x | 3.7% | 8.9% | 10.7% | 0.00% |
Similar Companies
These are the 12 companies most similar to Kiniksa Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Drug Manufacturers - Specialty & Generic.
| Company | About | Peers |
|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological... | NBIX competitors |
| Lantheus Holdings Inc (LNTH) | Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment... | LNTH competitors |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms... | AMRX competitors |
| Xeris Pharmaceuticals Inc (XERS) | Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. | XERS competitors |
| Elanco Animal Health (ELAN) | Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. | ELAN competitors |
| Dr. Reddy’s Laboratories Ltd ADR (RDY) | Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India. | RDY competitors |
| Indivior PLC Ordinary Shares (INDV) | Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence... | |
| Hims Hers Health Inc (HIMS) | Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. | HIMS competitors |
| HUTCHMED DRC (HCM) | HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. | |
| BioCryst Pharmaceuticals Inc (BCRX) | BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina. | BCRX competitors |
| Bausch Health Companies Inc (BHC) | Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical... | BHC competitors |
| United Therapeutics Corporation (UTHR) | United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs... | UTHR competitors |
Frequently Asked Questions About KNSA
Who are Kiniksa Pharmaceuticals' main competitors?
The companies most similar to Kiniksa Pharmaceuticals include Neurocrine Biosciences (NBIX), Lantheus Holdings (LNTH), Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX), Xeris Pharmaceuticals (XERS) and Elanco Animal Health (ELAN), listed from the closest match.
Who is Kiniksa Pharmaceuticals' biggest competitor?
United Therapeutics (UTHR) is the largest of the similar companies at $25.18B; Neurocrine Biosciences (NBIX) is the closest match by business profile, size, sector and industry.
How does KNSA stock compare with its competitors?
KNSA's P/E is 72.5x against a peer median of 19.9x; its P/S is 7.8x against a peer median of 3.0x; its net margin is 11.6% against a peer median of 3.7%.
Which of Kiniksa Pharmaceuticals' competitors pays a higher dividend?
Kiniksa Pharmaceuticals pays no dividend. Dr. Reddy’s Laboratories Ltd ADR (RDY) has a higher forward dividend yield; Dr. Reddy’s Laboratories Ltd ADR (RDY) has the highest at 0.44%.
Is Kiniksa Pharmaceuticals bigger than its competitors?
No. Kiniksa Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is United Therapeutics (UTHR) at $25.18B.
KNSA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts